Free Trial
NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Price, News & Analysis

Stoke Therapeutics logo
$19.56 -0.12 (-0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$19.65 +0.09 (+0.46%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Stoke Therapeutics Stock (NASDAQ:STOK)

Key Stats

Today's Range
$19.13
$19.91
50-Day Range
$11.35
$19.68
52-Week Range
$5.35
$19.91
Volume
1.15 million shs
Average Volume
807,226 shs
Market Capitalization
$1.07 billion
P/E Ratio
23.01
Dividend Yield
N/A
Price Target
$25.57
Consensus Rating
Buy

Company Overview

Stoke Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

STOK MarketRank™: 

Stoke Therapeutics scored higher than 91% of companies evaluated by MarketBeat, and ranked 107th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Stoke Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Stoke Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Stoke Therapeutics is 23.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.40.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Stoke Therapeutics is 23.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.15.

  • Price to Book Value per Share Ratio

    Stoke Therapeutics has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Stoke Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    23.13% of the float of Stoke Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently decreased by 0.61%, indicating that investor sentiment is improving.
  • Dividend Yield

    Stoke Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Stoke Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    23.13% of the float of Stoke Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently decreased by 0.61%, indicating that investor sentiment is improving.
  • News Sentiment

    Stoke Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 30 news articles for Stoke Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    18 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 260% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $345,775.00 in company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Stoke Therapeutics is held by insiders.

  • Read more about Stoke Therapeutics' insider trading history.
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

The Top 10 AI Stocks You Need to Know
Discover the 10 Best AI Stocks to Buy Now! The AI revolution is reshaping the investment landscape, and knowing where to place your bets is crucial. Our free report reveals the 10 top AI stocks that should be on your radar right now. Don't miss your chance to get in on these high-potential tech plays.tc pixel
FY2025 Earnings Estimate for STOK Issued By Chardan Capital
Leerink Partnrs Has Optimistic Outlook of STOK Q3 Earnings
HC Wainwright Issues Optimistic Forecast for STOK Earnings
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $22.00
See More Headlines

STOK Stock Analysis - Frequently Asked Questions

Stoke Therapeutics' stock was trading at $11.03 at the beginning of the year. Since then, STOK shares have increased by 77.3% and is now trading at $19.56.

Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its earnings results on Tuesday, August, 12th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. The firm earned $13.82 million during the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a trailing twelve-month return on equity of 18.32%.
Read the conference call transcript
.

Stoke Therapeutics (STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Top institutional investors of Stoke Therapeutics include Redmile Group LLC (8.01%), Skorpios Trust (5.96%), Marshall Wace LLP (4.21%) and Geode Capital Management LLC (1.78%). Insiders that own company stock include Skorpios Trust, Edward M Md Kaye, Stephen J Tulipano, Jonathan Allan and Barry Ticho.
View institutional ownership trends
.

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA).

Company Calendar

Last Earnings
8/12/2025
Today
8/22/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STOK
CIK
1623526
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$35.00
Low Price Target
$18.00
Potential Upside/Downside
+31.5%
Consensus Rating
Buy
Rating Score (0-4)
3.22
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.85
Trailing P/E Ratio
22.88
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.98 million
Net Margins
26.25%
Pretax Margin
26.90%
Return on Equity
18.32%
Return on Assets
15.48%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.98
Quick Ratio
6.98

Sales & Book Value

Annual Sales
$199.89 million
Price / Sales
5.33
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.11 per share
Price / Book
3.18

Miscellaneous

Outstanding Shares
54,797,000
Free Float
49,591,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
1.15

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:STOK) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners